INMD

InMode Ltd. is an Israel-based company operating in the healthcare sector within the medical-device industry, specializing in minimally invasive aesthetic technologies and energy-based treatment platforms.

The company develops and manufactures devices that use proprietary radiofrequency technologies to support body contouring, facial rejuvenation, tissue remodeling, fat reduction and dermatological applications.

Founded in 2008 by Moshe Mizrahy and a team of engineers experienced in aesthetic-energy systems, InMode emerged during a period of rapid global expansion in non-surgical cosmetic treatments.

Its founding purpose was to provide physicians with technologically advanced devices offering precise, controlled results with reduced downtime compared to traditional surgical procedures.

InMode’s portfolio includes well-known platforms such as BodyTite, FaceTite, Morpheus8, AccuTite, EmbraceRF, Votiva and Optimas, each designed for specific medical and aesthetic uses.

These solutions support plastic surgery, dermatology, gynecology, ENT procedures and general aesthetic medicine. The company focuses on radiofrequency-assisted lipolysis (RFAL) and fractional RF technology, enabling controlled thermal effects for tissue contraction, fat remodeling and skin improvement.

The company operates globally, distributing its products across North America, Europe, Asia-Pacific, the Middle East and Latin America.

Its operational structure includes R&D centers in Israel, engineering teams focused on hardware and embedded software, clinical-validation groups, regulatory-compliance divisions, direct sales teams, distributor partnerships and comprehensive physician-training programs.

Market factors influencing InMode include demand for minimally invasive procedures, technological evolution in energy-based devices, regulatory environments, competition with laser and ultrasound manufacturers, economic conditions affecting aesthetic spending, and broader trends in cosmetic medicine such as combination therapies, digital treatment planning and rising adoption among male patients.

InMode Ltd.’s shares trade on the Nasdaq under the ticker INMD.

History and when InMode Ltd. was founded

InMode was founded in 2008 in Israel by Moshe Mizrahy and engineering specialists who had prior experience in developing aesthetic-energy devices. At the time, the cosmetic-medicine industry was transitioning toward minimally invasive technologies capable of providing surgical-like results with significantly less downtime.

The founders identified a gap in the market for radiofrequency systems that could offer precision, safety and consistency for both physicians and patients.

During its early development phase, the company focused on refining RFAL technology, creating platforms capable of combining fat remodeling with deep tissue contraction.

The success of early systems allowed InMode to gain traction among surgeons and aesthetic practitioners seeking alternatives to traditional liposuction and facelift surgery.

Throughout the 2010s, InMode broadened its product line, launching platforms for facial rejuvenation, body sculpting, gynecological applications and dermatological resurfacing. Technologies such as Morpheus8 became flagship components of its portfolio, contributing to rapid international expansion.

The company strengthened its distributor network, increased its presence in major global markets and invested in clinical studies to support product adoption.

In 2019, the company conducted its Initial Public Offering (IPO) on the Nasdaq, raising capital to expand manufacturing, accelerate R&D and increase commercial reach. The IPO represented a major milestone, positioning InMode as a notable global player in aesthetic technology.

From 2020 to 2024, the company experienced a surge in demand for minimally invasive aesthetic procedures, driven by shifts in consumer behavior and growth of the cosmetic-medicine market.

InMode enhanced its product lines, integrated advanced software capabilities and expanded training programs for clinicians. At the same time, the company faced intensified competition and evolving regulatory requirements, prompting continued investment in innovation and compliance.

By 2024, InMode Ltd. had established itself as a global leader in radiofrequency-based aesthetic technologies, known for offering versatile, clinically validated platforms that support high-precision minimally invasive procedures.

Additional Information

InMode Ltd. (United States) is listed on the Nasdaq and has a market capitalization of $868.77 Millions, with shareholders equity totaling $683.20 Millions.

The company employs approximately 311 people and operates in the Health sector, within the Medical Supplies and Equipment industry.

Over the past 12 months, InMode Ltd. reported $370.49 Millions in revenue, generating net income of $93.82 Millions.

Key financial metrics include a P/E ratio of 9.26, a price-to-book (P/B) ratio of 1.27, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker INMD.